Search results for "Hematologi"

showing 10 items of 194 documents

Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children

2010

International audience; We studied lymphocyte recovery in 88 children who consecutively underwent unrelated cord blood transplantation for malignant (n = 64) or nonmalignant (n = 24) diseases. All children but 3 received myeloablative conditioning regimens with pretransplant antithymocyte globulin. Median age was 5.6 years (0.1-18 years) and median follow-up was 40 months (10-136 months). The median dose of infused viable CD45(+) cells (vCD45) was 3.35 × 10(7)/kg with a ratio infused vCD45/collected total nucleated cell at 0.46. Immunologic endpoints were: time to achieve CD3(+) >500 and 1500/mm(3), CD4(+) >500/mm(3), CD8(+) >250/mm(3), CD19(+) >200/mm(3), natural killer >100/mm(3). These e…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyLymphocyteMESH: Antigens CD/analysisCell Count[SDV.GEN] Life Sciences [q-bio]/GeneticsMESH : Child PreschoolGastroenterology0302 clinical medicineMESH : ChildMESH: Child[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyChildChildrenMESH : Lymphocyte Count0303 health sciencesMESH : Cell SurvivalbiologyIncidence (epidemiology)Graft Survival[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematology3. Good healthMESH: Hematologic Diseases/therapy Humansmedicine.anatomical_structureQuartileMESH: Cell SurvivalMESH: Cord Blood Stem Cell Transplantation/methodsLymphocytes recoveryChild PreschoolMESH : Immunophenotyping[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Infant KineticsCord Blood Stem Cell Transplantationmedicine.medical_specialtyMESH: Lymphocyte CountGlobulinMESH: ImmunophenotypingAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyCell SurvivalContext (language use)MESH : Hematologic Diseases/therapy HumansCD19Immunophenotyping03 medical and health sciencesMESH : Lymphocyte Subsets/cytologyAntigens CDInternal medicineMESH : AdolescentmedicineHumansLymphocyte CountMESH : Infant KineticsMESH : Antigens CD45* Cell Count030304 developmental biologyMESH: AdolescentTransplantation[SDV.GEN]Life Sciences [q-bio]/GeneticsUmbilical cord blood transplantationMESH : Graft Survival/immunologybusiness.industryUmbilical Cord Blood TransplantationMESH: Child PreschoolMESH : Cord Blood Stem Cell Transplantation/methodsInfantMESH : Antigens CD/analysisHematologic DiseasesLymphocyte SubsetsSurgeryMESH: Lymphocyte Subsets/cytologyKineticsbiology.proteinMESH: Antigens CD45* Cell CountLeukocyte Common Antigensbusiness[ SDV.GEN ] Life Sciences [q-bio]/GeneticsMESH: Graft Survival/immunologyCD8030215 immunology
researchProduct

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

2015

International audience; Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of interleukin-3 receptor α chain (IL3-Rα or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and …

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyMalePathology[SDV]Life Sciences [q-bio]ApoptosisMice SCIDMice0302 clinical medicineMice Inbred NODhemic and lymphatic diseasesTumor Cells CulturedMedicineCytotoxic T cellNeoplasm[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyCytotoxicityAged 80 and overmedicine.diagnostic_test[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyArticlesMiddle AgedFlow Cytometry3. Good health[SDV] Life Sciences [q-bio]030220 oncology & carcinogenesisHematologic NeoplasmsFemaleAdultmedicine.medical_specialtyRecombinant Fusion ProteinsBlotting WesternInterleukin-3 Receptor alpha Subunit[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologyIn Vitro TechniquesFlow cytometry03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerBiomarkers TumorAnimalsHumans[SDV.BC] Life Sciences [q-bio]/Cellular BiologyAgedCell ProliferationMyeloproliferative Disordersbusiness.industryCell growthDendritic Cellsmedicine.diseaseXenograft Model Antitumor Assaysstomatognathic diseasesCell cultureApoptosisCancer researchInterleukin-3 receptorbusiness030215 immunologyPlasmacytomaHaematologica
researchProduct

The bone marrow stroma in hematological neoplasms-a guilty bystander.

2011

In the setting of hematological neoplasms, changes in the bone marrow (BM) stroma might arise from pressure exerted by the neoplastic clone in shaping a supportive microenvironment, or from chronic perturbation of the BM homeostasis. Under such conditions, alterations in the composition of the BM stroma can be profound, and could emerge as relevant prognostic factors. In this Review, we delineate the multifaceted contribution of the BM stroma to the pathobiology of several hematological neoplasms, and discuss the impact of stromal modifications on the natural course of these diseases. Specifically, we highlight the involvement of BM stromal components in lymphoid and myeloid malignancies, a…

hematological malignancies.bone marrow stroma
researchProduct

Incidencia y factores pronósticos para el desarrollo de infección fúngica invasiva en pacientes hematológicos de alto riesgo

2022

La infección fúngica invasiva (IFI) es una causa cada vez más frecuente de morbi-mortalidad en pacientes con enfermedades hematológicas malignas en tratamiento con quimioterapia intensiva y los receptores de un trasplante alogénico de progenitores hematopoyético (alo-TPH). El objetivo de esta tesis por compendio de publicaciones fue realizar un estudio epidemiológico de la IFI en nuestro entorno y, recoger la práctica clínica habitual en la profilaxis y el tratamiento de la IFI. Para ello se recogen los resultados de tres estudios publicados en revistas de alto impacto especializadas en hematología y trasplante hematopoyético. Los estudios comparten un nexo común, el análisis de las infecci…

inmunodepresiónenfermedades hematologicas:CIENCIAS MÉDICAS ::Medicina interna::Hematología [UNESCO]infección fúngica invasivaUNESCO::CIENCIAS MÉDICAS ::Medicina interna::Hematología
researchProduct

Correlations of blood selenium with hematological parameters in West German adults.

1988

The serum selenium and the whole blood selenium of 72 healthy persons (47 women, 25 men) was determined. There exist sex specific differences of the whole blood selenium between men (98 +/- 19 micrograms Se/L) and women (89 +/- 17 micrograms Se/L). The serum selenium did not show sex specific differences, but sex specific differences are found if the total amount of extracellular selenium is calculated by correction of the serum selenium with the hematocrit. Women have more extra-cellular selenium/L whole blood (40 +/- 8 micrograms Se) than men (36 +/- 7 micrograms Se). Men have more intraerythrocyte selenium (cellular selenium = 67 +/- 14 micrograms Se) in one L whole blood than women (52 …

inorganic chemicalsAdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistrychemistry.chemical_elementHematocritBiochemistryInorganic ChemistryLipid peroxidationchemistry.chemical_compoundSeleniumInternal medicineMolemedicineExtracellularHumansWhole bloodchemistry.chemical_classificationSex CharacteristicsHematologic Testsmedicine.diagnostic_testGlutathione peroxidaseSpectrophotometry AtomicBiochemistry (medical)Germany Westfood and beveragesGeneral MedicineEndocrinologychemistryFemaleHemoglobinSeleniumBiological trace element research
researchProduct

Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies

2011

The potent anti-tumor activities of γδ T cells, their ability to produce pro-inflammatory cytokines, and their strong cytolytic activity have prompted the development of protocols in which γδ agonists or ex vivo-expanded γδ cells are administered to tumor patients. γδ T cells can be selectively activated by either synthetic phosphoantigens or by drugs that enhance their accumulation into stressed cells as aminobisphosphonates, thus offering new avenues for the development of γδ T cell-based immunotherapies. The recent development of small drugs selectively activating Vγ9Vδ2 T lymphocytes, which upregulate the endogenous phosphoantigens, has enabled the investigators to design the experiment…

lcsh:Internal medicineCancer Researchbusiness.industryT cellmedicine.medical_treatmentCellImmunotherapylcsh:Other systems of medicineVc9Vd2 T cells - Hematologic malignancies - Immunotherapy - Cytokines - CytotoxicityVc9Vd2 T cells - Hematologic malignancies - Immunotherapy - Cytokines - Cytotoxicitylcsh:RZ201-999Vg9Vd2 T cells immunotherapy hematologic malignanciesIn vitroCytolysismedicine.anatomical_structureDownregulation and upregulationOncologyIn vivoImmunologymedicineCytotoxicitybusinesslcsh:RC31-1245Oncology Reviews
researchProduct

HEMATOLOGICAL VARIABILITY ANALYSIS AFTER ROAD MARATHON VS ULTRATRAIL. PREDICTIVE FACTORS

2020

The practice of long- and medium-distance races has exponentially increased the number of participants in recent years. They are carried out under extreme conditions that cause both biochemical and anthropometric changes in athletes and, in addition, have serious risks associated, such as dehydration, thermal disorders, or hypoglycemia. Knowledge regarding alterations at hematological level after this type of effort is limited. The objectives of this pre-post analytical descriptive observational study were: to describe and compare hematological values in amateur runners pre and post road marathon and ultratrail races, and to compare the hematological parameters between the groups in the two…

medicine.diagnostic_testWilcoxon signed-rank testbusiness.industrywhite blood cellsrunning; red blood cells; white blood cells; hematological changes; efforthematological changesUnivariatePhysical Therapy Sports Therapy and RehabilitationHematocritAnthropometryeffortLogistic regressionStatistical significancemedicineMann–Whitney U testrunningObservational studybusinesshuman activitiesDemographyred blood cellsKinesiology
researchProduct

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

2010

IMPORTANCE OF THE FIELDS Multiple myeloma (MM) is a hematological malignancy still remaining incurable despite the various therapies available, mainly because of the high fraction of refractory/relapsing cases. Therefore, the development of novel therapeutic approaches is urgently needed to overcome conventional treatment resistance. AREAS COVERED IN THIS REVIEW: In the era of targeted therapies, treatments combining a high specificity for neoplastic cells and the capability to interfere with environmental signals should be regarded as the weapons of choice. Monoclonal antibody (mAb)-based humoral immunotherapy could satisfy both these requirements when applied to MM. Indeed, many of the mo…

medicine.drug_classmedicine.medical_treatmentClinical BiochemistryCD38Monoclonal antibodyAntigens NeoplasmDrug DiscoverymedicineAnimalsHumansMultiple myelomamultiple myeloma; immunotherapyPharmacologyCD40biologybusiness.industryConventional treatmentAntibodies MonoclonalImmunotherapymedicine.diseaseImmunity Humoralmultiple myelomamultiple myeloma humoral immunotherapyHematological malignancyImmunologyMolecular targetsbiology.proteinimmunotherapybusiness
researchProduct

Immunologic characterization of COVID-19 patients with hematological cancer

2020

Not available.

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)SARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19CancerCOVID-19Hematologic Neoplasms Humans SARS-CoV-2HematologyHematologic Neoplasmsmedicine.diseaseVirologyHematologic NeoplasmsEpidemiologymedicineHumansLetters to the Editorbusiness
researchProduct

IVIG in APS pregnancy

2004

For more than two decades, the intravenous administration of high doses of IgG pooled from the plasma of healthy donors (immune globulin therapy, also known as ‘IVIG’) has benefited patients with a variety of autoimmune disorders. A potential therapeutic role of IVIG in the prevention of thrombosis and of miscarriages in antiphospholipid syndrome (APS) has been postulated. Multicenter randomized controlled trials attempted to define the role of IVIG in preventing pregnancy complications in APS indicate that simple anticoagulation could not be completely satisfactory, and certain patient subgroups might take advantage of IVIG therapy alone or in combination with heparin.

medicine.medical_specialtyAbortion Habitual030204 cardiovascular system & hematologyrecurrent fetal losslaw.invention03 medical and health sciences0302 clinical medicineRheumatologyRandomized controlled trialAntiphospholipid syndromelawPregnancyhemic and lymphatic diseasesInternal medicinemedicineHigh dosesHumans030203 arthritis & rheumatologyIVIGPregnancybiologybusiness.industryPregnancy Complications HematologicImmunoglobulins IntravenousThrombosisHeparinmedicine.diseaseAntiphospholipid SyndromeThrombosisPregnancy ComplicationsImmune Globulin TherapyImmunologybiology.proteinFemaleAntibodybusinessmedicine.drugAPS
researchProduct